Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal Vaccine and Checkpoint Inhibitor Responses
Authors:
- Dimitrios N. SidiropoulosDSDimitrios N. Sidiropoulos
- Zhehao ZhangZZZhehao Zhang
- Jennifer N. DurhamJDJennifer N. Durham
- Soren CharmsazSCSoren Charmsaz
- Nicole E. GrossNGNicole E. Gross
- Jae W. LeeJLJae W. Lee
- Yanyi SunYSYanyi Sun
- Susheel PerikalaSPSusheel Perikala
- Joseph A. TandurellaJTJoseph A. Tandurella
- Dmitrijs LvovsDLDmitrijs Lvovs
- Arik MitschangAMArik Mitschang
- Gerard LemsonGLGerard Lemson
- 12 January 2026
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 14 (3) , 399-410
Abstract
Combination vaccine and checkpoint inhibitor therapy has previously demonstrated immunologic responses in patients with pancreatic ductal adenocarcinoma (PDAC), although with limited efficacy. An urgent need to augment responses has warranted a deeper understanding of how each treatment modality contributes to the overall inflammatory response. Serial blood samples from patients with PDAC treated with GVAX, CRS-207, anti–CTLA-4, and/or anti–PD-1 therapies were profiled using two mass cytometry panels. Generating 260 cytometric profiles from 64 unique patients allowed us to create an annotated PDAC immunotherapy atlas. Analysis of this atlas revealed that although GVAX alone did not significantly alter T-cell relative frequencies, it induced T-cell activation and upregulated checkpoint expression. Adding anti–PD-1 blockade to GVAX further enhanced T-cell activation, whereas adding anti–CTLA-4 distinctly enhanced memory formation. Vaccine-mediated effects were similar, but GVAX promoted plasmacytoid dendritic cells more than CRS-207. Derived phenotypic patterns could also be projected onto tumor imaging data, underscoring the potential for discoveries relating treatment-induced peripheral signatures to changes in the tumor microenvironment. See related article by Bever et al., p. 411Keywords
All Related Versions
Funding Information
- The Lustgarten Foundation Pancreatic Cancer Research Grant
- National Cancer Institute (P01-CA247886-01A1)
- Stand Up To Cancer (SU2C)
- Emerson Cancer Research Fund
- Allegheny Health Network
- National Cancer Institute (U01-CA212007)
- National Cancer Institute (U01-CA253403)
- National Cancer Institute (R50-CA243627)
- Johns Hopkins University Discovery Award
- National Cancer Institute (SPORE GI P50-CA062924-24A1)
- National Cancer Institute (F31-CA268724-01)
- National Cancer Institute (R21-CA264004)
- National Cancer Institute (S10-OD034407)
This publication has 38 references indexed in Scilit:
- Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cellsCancer Cell, 2024
- Systems immunology spanning tumors, lymph nodes, and peripheryCell Reports Methods, 2023
- SciServer: A science platform for astronomy and beyondAstronomy and Computing, 2020
- Decomposing Cell Identity for Transfer Learning across Cellular Measurements, Platforms, Tissues, and SpeciesCell Systems, 2019
- Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint BlockadeCell, 2017
- Plasmacytoid dendritic cell role in cutaneous malignanciesJournal of Dermatological Science, 2016
- Mass Cytometry: Single Cells, Many FeaturesCell, 2016
- Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative PotentialCell, 2015
- FlowSOM: Using self‐organizing maps for visualization and interpretation of cytometry dataCytometry Part A, 2015
- GM-CSF Gene-Transduced Tumor VaccinesMolecular Therapy, 2005